Table 3.
Adverse Events during the 12-Week Open-Label Treatment Phase
| Adverse Events | Persistent PTH (n = 100) |
|---|---|
| All Events | |
| ≥ 1 Adverse Event | 78 |
| ≥ 1 Treatment-Related Adverse Event | 38 |
| ≥ 1 Serious Adverse Event | 0 |
| Any Adverse Event leading to Study Discontinuation | 2 |
| Adverse Events occurring in ≥ 2% of Patientsa | |
| Injection-Site Reactions | |
| Pain | 7 |
| Erythema | 5 |
| Hemorrhage | 3 |
| Acid Reflux | 1 |
| Constipation | 30 |
| Diarrhea | 2 |
| Dizziness | 9 |
| Dry Mouth | 4 |
| Fatigue | 5 |
| Hot Flashes | 3 |
| Influenza | 2 |
| Irregular Menstruation | 3 |
| Low Back Pain | 2 |
| Nausea | 7 |
| Palpitations | 2 |
| Upper Abdominal Pain | 5 |
| Worsened Headache | 8 |
Data are reported as number of patients. If a patient had the same adverse event more than once, it was counted only once